This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​Mylan's merger with Pfizer's off-patent business Upjohn being monitored by Australian watchdog

( November 19, 2019, 02:49 GMT | Official Statement) -- MLex Summary: Mylan’s plans to combine with Pfizer’s off-patent drug business Upjohn is being monitored by Australia’s competition watchdog — a step that usually precedes the opening of an informal, public review. In an entry on the website of the Australian Competition & Consumer Commission, the regulator said it was “aware of the proposed merger of Mylan and Upjohn” and was currently monitoring the global merger. “A public review will be commenced in due course, once the parties provide a submission,” the ACCC entry said. The deal was announced on July 29, 2019.  No indication has been given about the timing of an Australian review of the merger’s local implications.The ACCC website entry follows: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login